Carlino, Matteo S
Vanella, Vito
Girgis, Christina
Giannarelli, Diana
Guminski, Alex
Festino, Lucia
Kefford, Richard F
Menzies, Alexander M
Long, Georgina V
Ascierto, Paolo A
Article History
Received: 10 June 2016
Revised: 9 September 2016
Accepted: 19 September 2016
First Online: 6 October 2016
Competing interests
: MS Carlino participated in the advisory boards for Merck, Amgen, Novartis and Bristol Myer Squibb. AM Menzies participated in the advisory boards for Merck, Novartis and Bristol Myer Squibb. RF Kefford participated in the advisory boards for Merck, Amgen, Novartis and Bristol Myer Squibb. GV Long participated in the advisory boards of Amgen, Bristol Myer Squibb, Glaxosmithkline, Novartis, Provectus, Roche and Merck Inc. PA Ascierto participated in the advisory boards for Merck, Amgen, Novartis and Bristol Myer Squibb. The remaining authors declare no conflict of interest.